First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers
Background Inhibition of the epithelial sodium channel (ENaC) represents a mutation-agnostic therapeutic approach to restore airway surface liquid hydration and mucociliary clearance in patients with cystic fibrosis. BI 1265162 is an inhaled ENaC inhibitor with demonstrated preclinical efficacy. Met...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2021-02-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/7/1/00447-2020.full |